Skip to main content
Clinical Trials/NL-OMON54987
NL-OMON54987
Recruiting
Not Applicable

The COMplement Prospective Evaluation of Thrombotic microangiopathy on Endothelium (COMPETE) Study - COMPETE

Medisch Universitair Ziekenhuis Maastricht0 sites42 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
atypical hemolytic uremic syndrome
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
42
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • \- Males or females at least 18 years of age;
  • \- Have acute kidney injury, defined as estimated GFR \<45 mL/min/1\.73m2;
  • \- Have documented TMA either on peripheral blood, defined as Coombs negative
  • microangiopathic hemolytic anemia (hematocrit \<30%, hemoglobin \<6\.5 mmol/L \[\<10
  • g/dL], lactate dehydrogenase \>500 U/L, and either schistocytes on peripheral
  • blood smear or undetectable haptoglobin), and platelets \<150,000 per µL, or
  • kidney biopsy;
  • \- Have primary atypical HUS or a coexisting condition linked to C\-TMA:

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • \- Have secondary causes of hypertensive emergency, including renovascular
  • hypertension, Cushing syndrome, aldosteronism, pheochromocytoma, thyroid
  • \- Have a nephropathy not related to thrombosis on kidney biopsy;
  • \- Have ADAMTS13 deficiency, defined as ADAMTS13 activity \<10%;
  • \- Have a positive stool culture for Shiga toxin producing bacteria;
  • \- Have positive serologic test for viral infections, including HIV and CMV;
  • \- Have a history of malignant disease, excluding non\-melanoma skin cancer;
  • \- Have a history of bone marrow or solid organ transplantation;

Outcomes

Primary Outcomes

Not specified

Similar Trials